Germ Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell Receptor

被引:125
作者
Cole, David K. [1 ]
Yuan, Fang [2 ]
Rizkallah, Pierre J. [1 ,3 ]
Miles, John J. [1 ,4 ]
Gostick, Emma [1 ]
Price, David A. [1 ]
Gao, George F. [5 ]
Jakobsen, Bent K. [6 ]
Sewell, Andrew K. [1 ]
机构
[1] Cardiff Univ, Sch Med, Dept Infect Immun & Biochem, Cardiff CF14 4XN, S Glam, Wales
[2] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England
[3] STFC Daresbury Lab, Warrington WA4 4AD, Cheshire, England
[4] Univ Queensland, Queensland Inst Med Res, Cellular Immunol Lab, Brisbane, Qld 4029, Australia
[5] Chinese Acad Sci, Inst Microbiol, Beijing 100101, Peoples R China
[6] Immunocore Ltd, Abingdon OX14 4RX, Oxon, England
基金
英国生物技术与生命科学研究理事会;
关键词
COMPLEX CLASS-I; TUMOR-REACTIVE CTL; PEPTIDE VACCINES; STRUCTURAL BASIS; ANTIGEN; ALPHA; IMMUNOGENICITY; AFFINITY; CHAIN; USAGE;
D O I
10.1074/jbc.M109.022509
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CD8(+) T-cells specific for MART-1-(26-35), a dominant melanoma epitope restricted by human leukocyte antigen (HLA)A* 0201, are exceptionally common in the naive T-cell repertoire. Remarkably, the TRAV12-2 gene is used to encode the T-cell receptor alpha(TCR alpha) chain in > 87% of these T-cells. Here, the molecular basis for this genetic bias is revealed from the structural and thermodynamic properties of an archetypal TRAV12-2-encoded TCR complexed to the clinically relevant heteroclitic peptide, ELAGIGILTV, bound to HLA-A*0201 (A2ELA). Unusually, the TRAV12-2 germ line-encoded regions of the TCR dominate the major atomic contacts with the peptide at the TCR/A2-ELA interface. This "innate" pattern of antigen recognition probably explains the unique characteristics and extraordinary frequencies of CD8(+) T-cell responses to this epitope.
引用
收藏
页码:27281 / 27289
页数:9
相关论文
共 52 条
[31]   Refinement of macromolecular structures by the maximum-likelihood method [J].
Murshudov, GN ;
Vagin, AA ;
Dodson, EJ .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 1997, 53 :240-255
[32]   Melan-A/MART-1-specific CD8 T cells: from thymus to tumor [J].
Pittet, MJ ;
Zippelius, A ;
Valmori, D ;
Speiser, DE ;
Cerottini, JC ;
Romero, P .
TRENDS IN IMMUNOLOGY, 2002, 23 (07) :325-328
[33]   High frequencies of naive Melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals [J].
Pittet, MJ ;
Valmori, D ;
Dunbar, PR ;
Speiser, DE ;
Liénard, D ;
Lejeune, F ;
Fleischhauer, K ;
Cerundolo, V ;
Cerottini, JC ;
Romero, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (05) :705-715
[34]   Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma [J].
Romero, P ;
Valmori, D ;
Pittet, MJ ;
Zippelius, A ;
Rimoldi, D ;
Lévy, F ;
Dutoit, V ;
Ayyoub, M ;
Rubio-Godoy, V ;
Michielin, O ;
Guillaume, P ;
Batard, P ;
Luescher, IF ;
Lejeune, F ;
Liénard, D ;
Rufer, N ;
Dietrich, PY ;
Speiser, DE ;
Cerottini, JC .
IMMUNOLOGICAL REVIEWS, 2002, 188 :81-96
[35]   How TCRs bind MHCs, peptides, and coreceptors [J].
Rudolph, Markus G. ;
Stanfield, Robyn L. ;
Wilson, Ian A. .
ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 :419-466
[36]   Crystal structures of two closely related but antigenically distinct HLA-A2/Melanocyte-Melanoma tumor-antigen peptide complexes [J].
Sliz, P ;
Michielin, O ;
Cerottini, JC ;
Luescher, I ;
Romero, P ;
Karplus, M ;
Wiley, DC .
JOURNAL OF IMMUNOLOGY, 2001, 167 (06) :3276-3284
[37]  
Speiser DE, 2002, EUR J IMMUNOL, V32, P731, DOI 10.1002/1521-4141(200203)32:3<731::AID-IMMU731>3.0.CO
[38]  
2-H
[39]   A structural basis for immunodominant human T cell receptor recognition [J].
Stewart-Jones, GBE ;
McMichael, AJ ;
Bell, JI ;
Stuart, DI ;
Jones, EY .
NATURE IMMUNOLOGY, 2003, 4 (07) :657-663
[40]  
Trautmann L, 2002, EUR J IMMUNOL, V32, P3181, DOI 10.1002/1521-4141(200211)32:11<3181::AID-IMMU3181>3.0.CO